Movatterモバイル変換


[0]ホーム

URL:


GT201500086A - Análogos de 2'-cloro nucleósido para infección por vhc - Google Patents

Análogos de 2'-cloro nucleósido para infección por vhc

Info

Publication number
GT201500086A
GT201500086AGT201500086AGT201500086AGT201500086AGT 201500086 AGT201500086 AGT 201500086AGT 201500086 AGT201500086 AGT 201500086AGT 201500086 AGT201500086 AGT 201500086AGT 201500086 AGT201500086 AGT 201500086A
Authority
GT
Guatemala
Prior art keywords
chlorine
hcv infection
nucleoside analog
compounds
nucleosid
Prior art date
Application number
GT201500086A
Other languages
English (en)
Inventor
Gilles Gosselin
Christophe Claude Parsy
Francois-Rene Alexandre
Houcine Rahali
Jean-François Griffon
Dominique Surleraux
Cyril B Dousson
Benjamin Alexander Mayes
Alistair James Stewart
David Dukhan
Claire Pierra
Adel M Moussa
Original Assignee
Univ Montpellier
Idenix Pharmaceuticals Llc
Centre National De La Rech Sc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=49354990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201500086(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Montpellier, Idenix Pharmaceuticals Llc, Centre National De La Rech ScfiledCriticalUniv Montpellier
Publication of GT201500086ApublicationCriticalpatent/GT201500086A/es

Links

Classifications

Landscapes

Abstract

EN EL PRESENTE DOCUMENTO SE PROPORCIONAN COMPUESTOS, COMPOSICIONES, Y MÉTODOS PARA EL TRATAMIENTO DE INFECCIONES POR FLAVIVIRIDAE, INCLUYENDO INFECCIONES POR VHC. EN CIERTAS REALIZACIONES, SE DESVELAN COMPUESTOS Y COMPOSICIONES DE DERIVADOS DE NUCLEÓSIDOS, QUE SE PUEDEN ADMINISTRAR SOLOS O EN COMBINACIÓN CON OTROS AGENTES ANTIVIRALES. EN CIERTAS REALIZACIONES, LOS COMPUESTOS SON 2' - CLORO NUCLEÓSIDOS O UNA SAL, SOLVATO, FORMA ESTEROISOMÉRICA, FORMA TAUTOMÉTICA O FORMA POLIMÓRFICA FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS.
GT201500086A2012-10-082015-04-07Análogos de 2'-cloro nucleósido para infección por vhcGT201500086A (es)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201261711131P2012-10-082012-10-08
US201361807249P2013-04-012013-04-01

Publications (1)

Publication NumberPublication Date
GT201500086Atrue GT201500086A (es)2018-12-19

Family

ID=49354990

Family Applications (1)

Application NumberTitlePriority DateFiling Date
GT201500086AGT201500086A (es)2012-10-082015-04-07Análogos de 2'-cloro nucleósido para infección por vhc

Country Status (30)

CountryLink
US (2)US10513534B2 (es)
EP (1)EP2906579B1 (es)
JP (1)JP6495822B2 (es)
KR (1)KR102001280B1 (es)
CN (2)CN104936970A (es)
AP (1)AP2015008384A0 (es)
AU (1)AU2013329521B2 (es)
BR (1)BR112015007698A2 (es)
CA (1)CA2887578A1 (es)
CL (1)CL2015000870A1 (es)
CR (1)CR20150199A (es)
DO (1)DOP2015000079A (es)
EA (1)EA030189B8 (es)
EC (1)ECSP15015737A (es)
ES (1)ES2674980T3 (es)
GE (1)GEP201706723B (es)
GT (1)GT201500086A (es)
HK (1)HK1207647A1 (es)
IL (1)IL238088A0 (es)
MD (1)MD20150036A2 (es)
MX (1)MX353422B (es)
NI (1)NI201500049A (es)
NZ (1)NZ706985A (es)
PE (1)PE20151318A1 (es)
PH (1)PH12015500749A1 (es)
SG (1)SG11201502750UA (es)
TN (1)TN2015000117A1 (es)
TR (1)TR201809048T4 (es)
WO (1)WO2014058801A1 (es)
ZA (1)ZA201502545B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
MY164523A (en)2000-05-232017-12-29Univ Degli Studi CagliariMethods and compositions for treating hepatitis c virus
BR0111196A (pt)2000-05-262004-04-06Idenix Cayman LtdComposições e uso das mesmas para tratamento de flavivìrus e pestivìrus
WO2004046331A2 (en)2002-11-152004-06-03Idenix (Cayman) Limited2’-branched nucleosides and flaviviridae mutation
US7951789B2 (en)2006-12-282011-05-31Idenix Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012154321A1 (en)2011-03-312012-11-15Idenix Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es)2011-09-122014-06-11Idenix Pharmaceuticals IncCompuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
US9296778B2 (en)2012-05-222016-03-29Idenix Pharmaceuticals, Inc.3′,5′-cyclic phosphate prodrugs for HCV infection
CA2873315A1 (en)2012-05-222013-11-28Idenix Pharamaceuticals, Inc.D-amino acid compounds for liver disease
US9109001B2 (en)2012-05-222015-08-18Idenix Pharmaceuticals, Inc.3′,5′-cyclic phosphoramidate prodrugs for HCV infection
AU2013265194B2 (en)2012-05-252018-01-04Janssen Sciences Ireland UcUracyl spirooxetane nucleosides
EP2900682A1 (en)2012-09-272015-08-05IDENIX Pharmaceuticals, Inc.Esters and malonates of sate prodrugs
TR201809048T4 (tr)2012-10-082018-07-23Centre Nat Rech ScientHcv enfeksiyonu için 2'-kloro nükleosit analogları.
US9211300B2 (en)2012-12-192015-12-15Idenix Pharmaceuticals Llc4′-fluoro nucleosides for the treatment of HCV
WO2014137930A1 (en)*2013-03-042014-09-12Idenix Pharmaceuticals, Inc.Thiophosphate nucleosides for the treatment of hcv
US9309275B2 (en)2013-03-042016-04-12Idenix Pharmaceuticals Llc3′-deoxy nucleosides for the treatment of HCV
EP2970357B1 (en)2013-03-132025-01-01Idenix Pharmaceuticals LLCAmino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en)2013-04-012021-09-15Idenix Pharmaceuticals LLC2',4'-fluoro nucleosides for the treatment of hcv
JP6476591B2 (ja)*2013-06-052019-03-06セントラル硝子株式会社(2R)−2−フルオロ−2−C−メチル−D−リボノ−γ−ラクトン類の製造方法
EP3004130B1 (en)2013-06-052019-08-07Idenix Pharmaceuticals LLC.1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en)*2013-08-012022-01-05Idenix Pharmaceuticals LLCD-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US20160271160A1 (en)*2013-10-172016-09-22Medivir AbHcv polymerase inhibitors
UA119050C2 (uk)2013-11-112019-04-25Ґілеад Саєнсиз, Інк.ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
US20170066795A1 (en)2014-03-052017-03-09Idenix Pharmaceuticals LlcSolid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
US10202411B2 (en)2014-04-162019-02-12Idenix Pharmaceuticals Llc3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
EP3203995A4 (en)2014-10-092019-05-15Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
WO2016064797A1 (en)2014-10-202016-04-28Merck Sharp & Dohme Corp.Process for making nucleoside phosphoramidate compounds
HK1243712A1 (zh)*2015-03-022018-07-20美迪维尔公司作為用於治療丙型肝炎的hcv抑制劑的核苷酸衍生物
US20180036330A1 (en)*2015-03-022018-02-08Medivir AbNucleotide phosphoramidate formulation
WO2016144918A1 (en)2015-03-062016-09-15Atea Pharmaceuticals, Inc.β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
US10618926B2 (en)2015-04-022020-04-14Merck Sharp & DohmeProcess for making phosphoramidate protected nucleoside compounds
CA2997170A1 (en)2015-09-022017-03-09Abbvie Inc.Anti-viral tetrahydrofurane derivatives
CN106543252A (zh)*2015-09-162017-03-29博瑞生物医药(苏州)股份有限公司核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh)2015-09-162017-03-29博瑞生物医药(苏州)股份有限公司氨基磷酸酯化合物及其制备方法和晶体
CN106478753A (zh)2015-09-162017-03-08博瑞生物医药(苏州)股份有限公司一种nuc‑1031单一异构体的制备方法和用途
CN105348345A (zh)*2015-12-152016-02-24杭州和正医药有限公司一种含有硫普罗宁结构的前药、其制备方法、药物组合物及其用途
US10214554B2 (en)2016-02-082019-02-26Merck Sharp & Dohme Corp.Process for making chloro-substituted nucleoside phosphoramidate compounds
WO2017223012A1 (en)2016-06-202017-12-28Merck Sharp & Dohme Corp.Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
WO2017223020A1 (en)*2016-06-202017-12-28Merck Sharp & Dohme Corp.Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
SG11201901457TA (en)2016-09-072019-03-28Atea Pharmaceuticals Inc2'-substituted-n6-substituted purine nucleotides for rna virus treatment
WO2018091542A1 (en)*2016-11-212018-05-24Idenix Pharmaceuticals LlcCyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
CA3126348A1 (en)2018-01-122020-07-18Board Of Regents Of The University Of NebraskaAntiviral prodrugs and formulations thereof
WO2019199756A1 (en)2018-04-092019-10-17Board Of Regents Of The University Of NebraskaAntiviral prodrugs and formulations thereof
US11292810B2 (en)2018-12-182022-04-05Merck Sharp & Dohme Corp.Inclusion complexes of an HCV NS5B inhibitor and uses thereof
TWI775313B (zh)2020-02-182022-08-21美商基利科學股份有限公司抗病毒化合物
TWI794742B (zh)2020-02-182023-03-01美商基利科學股份有限公司抗病毒化合物
KR20220143064A (ko)2020-02-182022-10-24길리애드 사이언시즈, 인코포레이티드항바이러스 화합물
EP4323362B1 (en)2021-04-162025-05-07Gilead Sciences, Inc.Methods of preparing carbanucleosides using amides
WO2023023527A1 (en)2021-08-182023-02-23Gilead Sciences, Inc.Phospholipid compounds and methods of making and using the same
CN115894458A (zh)*2022-08-312023-04-04合肥华纳生物医药科技有限公司一种新型修饰核苷及其在核酸药物中的应用

Family Cites Families (286)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3480613A (en)1967-07-031969-11-25Merck & Co Inc2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
US3536809A (en)1969-02-171970-10-27Alza CorpMedication method
US3598123A (en)1969-04-011971-08-10Alza CorpBandage for administering drugs
US3845770A (en)1972-06-051974-11-05Alza CorpOsmatic dispensing device for releasing beneficial agent
US3916899A (en)1973-04-251975-11-04Alza CorpOsmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)1976-02-021977-02-22Alza CorporationOsmotic system having laminar arrangement for programming delivery of active agent
US4526988A (en)1983-03-101985-07-02Eli Lilly And CompanyDifluoro antivirals and intermediate therefor
HU196714B (en)1984-10-041989-01-30Monsanto CoProcess for producing non-aqueous composition comprising somatotropin
IE58110B1 (en)1984-10-301993-07-14Elan Corp PlcControlled release powder and process for its preparation
US5073543A (en)1988-07-211991-12-17G. D. Searle & Co.Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)1989-03-221991-07-25Bioresearch SpaImpiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en)1989-07-071997-12-23Novartis IncSustained release formulations of water soluble peptides.
US5120548A (en)1989-11-071992-06-09Merck & Co., Inc.Swelling modulated polymeric drug delivery device
US5026687A (en)1990-01-031991-06-25The United States Of America As Represented By The Department Of Health And Human ServicesTreatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DE69132332T2 (de)1990-04-062000-11-30Genelabs Technologies, Inc.Hepatitis c-virus-epitope
US5733566A (en)1990-05-151998-03-31Alkermes Controlled Therapeutics Inc. IiControlled release of antiparasitic agents in animals
US5580578A (en)1992-01-271996-12-03Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4207363A1 (de)1992-03-041993-09-09Max Delbrueck CentrumAntivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
US5610054A (en)1992-05-141997-03-11Ribozyme Pharmaceuticals, Inc.Enzymatic RNA molecule targeted against Hepatitis C virus
US6995146B2 (en)1992-09-102006-02-07Isis Pharmaceuticals, Inc.Compositions and methods for treatment of hepatitis C virus-associated diseases
EP0662157B1 (en)1992-09-102001-06-20Isis Pharmaceuticals, Inc.Compositions and methods for treatment of hepatitis c virus-associated diseases
US6174868B1 (en)1992-09-102001-01-16Isis Pharmaceuticals, Inc.Compositions and methods for treatment of hepatitis C virus-associated diseases
US6433159B1 (en)1992-09-102002-08-13Isis Pharmaceuticals, Inc.Compositions and methods for treatment of Hepatitis C virus associated diseases
US6423489B1 (en)1992-09-102002-07-23Isis Pharmaceuticals, Inc.Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6391542B1 (en)1992-09-102002-05-21Isis Pharmaceuticals, Inc.Compositions and methods for treatment of Hepatitis C virus-associated diseases
TW333456B (en)1992-12-071998-06-11Takeda Pharm Ind Co LtdA pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en)1993-01-251997-01-07Pharmetrix CorporationLiquid reservoir transdermal patch for the administration of ketorolac
ATE181557T1 (de)1993-02-241999-07-15Jui H WangZusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren
US6087324A (en)1993-06-242000-07-11Takeda Chemical Industries, Ltd.Sustained-release preparation
US5846964A (en)1993-07-191998-12-08Tokyo Tanabe Company LimitedHepatitis C virus proliferation inhibitor
DE4415539C2 (de)1994-05-031996-08-01Osama Dr Dr Med OmerPflanzen mit virustatischer und antiviraler Wirkung
IT1270594B (it)1994-07-071997-05-07Recordati Chem PharmComposizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4432623A1 (de)1994-09-141996-03-21Huels Chemische Werke AgVerfahren zur Bleichung von wäßrigen Tensidlösungen
GB9505025D0 (en)1995-03-131995-05-03Medical Res CouncilChemical compounds
JP3786447B2 (ja)1995-03-312006-06-14エーザイ株式会社C型肝炎の予防・治療剤
ATE268591T1 (de)1995-06-272004-06-15Takeda Chemical Industries LtdVerfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en)1995-09-042001-08-01Takeda Chemical Industries LtdMethod of production of sustained-release preparation
JP2909418B2 (ja)1995-09-181999-06-23株式会社資生堂薬物の遅延放出型マイクロスフイア
US5980945A (en)1996-01-161999-11-09Societe De Conseils De Recherches Et D'applications Scientifique S.A.Sustained release drug formulations
EP0914421A2 (en)1996-02-291999-05-12Immusol, Inc.Hepatitis c virus ribozymes
US5633388A (en)1996-03-291997-05-27Viropharma IncorporatedCompounds, compositions and methods for treatment of hepatitis C
US5830905A (en)1996-03-291998-11-03Viropharma IncorporatedCompounds, compositions and methods for treatment of hepatitis C
US5990276A (en)1996-05-101999-11-23Schering CorporationSynthetic inhibitors of hepatitis C virus NS3 protease
US5891874A (en)1996-06-051999-04-06Eli Lilly And CompanyAnti-viral compound
US6264970B1 (en)1996-06-262001-07-24Takeda Chemical Industries, Ltd.Sustained-release preparation
US5837257A (en)1996-07-091998-11-17Sage R&DUse of plant extracts for treatment of HIV, HCV and HBV infections
GB9617177D0 (en)1996-08-151996-09-25Kvaerner H & G Offshore LtdDownhole valve actuation
US6419961B1 (en)1996-08-292002-07-16Takeda Chemical Industries, Ltd.Sustained release microcapsules of a bioactive substance and a biodegradable polymer
JP3927630B2 (ja)1996-09-272007-06-13エーザイ・アール・アンド・ディー・マネジメント株式会社ウイルス感染症の予防・治療剤
US5922757A (en)1996-09-301999-07-13The Regents Of The University Of CaliforniaTreatment and prevention of hepatic disorders
CA2217134A1 (en)1996-10-091998-04-09Sumitomo Pharmaceuticals Co., Ltd.Sustained release formulation
ES2169880T3 (es)1996-10-182002-07-16Vertex PharmaInhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
EP0839525B1 (en)1996-10-312004-08-04Takeda Chemical Industries, Ltd.Sustained-release preparation
GB9623908D0 (en)1996-11-181997-01-08Hoffmann La RocheAmino acid derivatives
IL119833A (en)1996-12-152001-01-11Lavie DavidHypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
DK0946169T3 (da)1996-12-202003-04-22Takeda Chemical Industries LtdFremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en)1997-01-291999-04-06Poli Industria Chimica, S.P.A.Time-specific controlled release dosage formulations and method of preparing same
US6004933A (en)1997-04-251999-12-21Cortech Inc.Cysteine protease inhibitors
GB9708611D0 (en)1997-04-281997-06-18Univ CardiffChemical compounds
JP3963488B2 (ja)1997-06-302007-08-22メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツンク ウント コンパニー コマンディゲゼルシャフト アウフ アクチェン1−アミノ−アルキルシクロヘキサンnmda受容体拮抗薬
DE69827956T2 (de)1997-08-112005-04-14Boehringer Ingelheim (Canada) Ltd., LavalPeptidanaloga mit inhibitorischer wirkung auf hepatitis c
EA200700564A1 (ru)1998-02-252007-08-31Эмори Юниверсити2`-фторнуклеозиды
US6613358B2 (en)1998-03-182003-09-02Theodore W. RandolphSustained-release composition including amorphous polymer
GB9806815D0 (en)1998-03-301998-05-27Hoffmann La RocheAmino acid derivatives
KR19990085365A (ko)1998-05-161999-12-06허영섭지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6833361B2 (en)1998-05-262004-12-21Ribapharm, Inc.Nucleosides having bicyclic sugar moiety
US6323180B1 (en)1998-08-102001-11-27Boehringer Ingelheim (Canada) LtdHepatitis C inhibitor tri-peptides
GB9821058D0 (en)1998-09-281998-11-18Univ CardiffChemical compound
CN1346360A (zh)1999-02-122002-04-24葛兰素集团有限公司作为抗病毒剂的(1r,顺式)-4-(6-氨基-9h-嘌呤-9-基)-2-环戊烯-1-甲醇的氨基磷酸酯及一二和三磷酸酯
US6248363B1 (en)1999-11-232001-06-19Lipocine, Inc.Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1225899A2 (en)1999-11-042002-07-31Virochem Pharma Inc.Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
CA2400274A1 (en)2000-02-182001-08-23Shire Biochem Inc.Method for the treatment or prevention of flavivirus infections using nucleoside analogues
US7094770B2 (en)2000-04-132006-08-22Pharmasset, Ltd.3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
GB0009486D0 (en)2000-04-172000-06-07Univ CardiffChemical compounds
GB0011203D0 (en)2000-05-092000-06-28Univ CardiffChemical compounds
MY164523A (en)2000-05-232017-12-29Univ Degli Studi CagliariMethods and compositions for treating hepatitis c virus
BR0111196A (pt)2000-05-262004-04-06Idenix Cayman LtdComposições e uso das mesmas para tratamento de flavivìrus e pestivìrus
MXPA03000626A (es)2000-07-212004-07-30Schering CorpNuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
AR029851A1 (es)2000-07-212003-07-16Dendreon CorpNuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es)2000-07-212004-02-04Schering CorpImidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
CA2418199A1 (en)2000-07-212002-01-31Corvas International, Inc.Peptides as ns3-serine protease inhibitors of hepatitis c virus
US20030008841A1 (en)2000-08-302003-01-09Rene DevosAnti-HCV nucleoside derivatives
CN1133642C (zh)2000-10-092004-01-07清华大学核苷5’-硫代磷酰氨基酸酯化合物
PT2251015E (pt)2000-10-182013-04-15Gilead Pharmasset LlcNucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal
AU2002248147B2 (en)2000-11-202006-04-06Bristol-Myers Squibb CompanyHepatitis C tripeptide inhibitors
AU2002236591B2 (en)2000-12-122005-07-14Schering CorporationDiaryl peptides as NS3-serine protease inhibitors of hepatits C virus
AU2002230763A1 (en)2000-12-132008-01-03Bristol-Myers Squibb Pharma CompanyInhibitors of hepatitis c virus ns3 protease
US6653295B2 (en)2000-12-132003-11-25Bristol-Myers Squibb CompanyInhibitors of hepatitis C virus NS3 protease
AU2002230764A1 (en)2000-12-132002-06-24Bristol-Myers Squibb Pharma CompanyImidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
US20040266723A1 (en)2000-12-152004-12-30Otto Michael J.Antiviral agents for treatment of Flaviviridae infections
US7105499B2 (en)2001-01-222006-09-12Merck & Co., Inc.Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002243791B2 (en)2001-01-222006-06-29Isis Pharmaceuticals, Inc.Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US8481712B2 (en)2001-01-222013-07-09Merck Sharp & Dohme Corp.Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2002070533A2 (en)2001-03-012002-09-12Pharmasset Ltd.Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides
US20040209831A1 (en)2002-02-202004-10-21Mcswiggen JamesRNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
GB0112617D0 (en)2001-05-232001-07-18Hoffmann La RocheAntiviral nucleoside derivatives
GB0114286D0 (en)2001-06-122001-08-01Hoffmann La RocheNucleoside Derivatives
EP1404694A1 (en)2001-06-212004-04-07Glaxo Group LimitedNucleoside compounds in hcv
US7022323B2 (en)2001-06-262006-04-04Progenics Pharmaceuticals, Inc.Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
WO2003026589A2 (en)2001-09-282003-04-03Idenix (Cayman) LimitedMethods and compositions for treating hepatitis c virus using 4'-modified nucleosides
EP1438054A4 (en)2001-09-282006-07-26Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
US6867185B2 (en)2001-12-202005-03-15Bristol-Myers Squibb CompanyInhibitors of hepatitis C virus
US7091184B2 (en)2002-02-012006-08-15Boehringer Ingelheim International GmbhHepatitis C inhibitor tri-peptides
CA2369970A1 (en)2002-02-012003-08-01Boehringer Ingelheim (Canada) Ltd.Hepatitis c inhibitor tri-peptides
US6642204B2 (en)2002-02-012003-11-04Boehringer Ingelheim International GmbhHepatitis C inhibitor tri-peptides
CA2370396A1 (en)2002-02-012003-08-01Boehringer Ingelheim (Canada) Ltd.Hepatitis c inhibitor tri-peptides
AU2003209045B2 (en)2002-02-132006-12-14Isis Pharmaceuticals, Inc.Methods of inhibiting orthopoxvirus replication with nucleoside compounds
ATE519774T1 (de)2002-02-202011-08-15Sirna Therapeutics IncDurch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina)
US7285658B2 (en)2002-02-282007-10-23Biota, Inc.Nucleotide mimics and their prodrugs
AU2003301959A1 (en)2002-05-202004-06-03Bristol-Myers Squibb CompanySubstituted cycloalkyl p1' hepatitis c virus inhibitors
US6869964B2 (en)2002-05-202005-03-22Bristol-Myers Squibb CompanyHeterocyclicsulfonamide hepatitis C virus inhibitors
MY140680A (en)2002-05-202010-01-15Bristol Myers Squibb CoHepatitis c virus inhibitors
DE60336550D1 (de)2002-05-202011-05-12Bristol Myers Squibb CoInhibitoren des hepatitis-c-virus
US20040014108A1 (en)2002-05-242004-01-22Eldrup Anne B.Oligonucleotides having modified nucleoside units
AU2003251524A1 (en)2002-06-172003-12-31Isis Pharmaceuticals, Inc.Carbocyclic nucleoside analogs as RNA-antivirals
EP1551421A2 (en)2002-06-212005-07-13Merck & Co. Inc.Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2006512288A (ja)2002-06-272006-04-13メルク エンド カムパニー インコーポレーテッドRna依存性rnaウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
CN103275159A (zh)2002-06-282013-09-04埃迪尼克斯医药公司用于治疗黄病毒感染的修饰的2’和3’-核苷前药
JP5087211B2 (ja)2002-06-282012-12-05イデニクス(ケイマン)リミテツドフラビウィルス感染治療のための2′および3′−ヌクレオシドプロドラッグ
NZ537662A (en)2002-06-282007-10-26Idenix Cayman Ltd2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
KR20050035194A (ko)2002-06-282005-04-15이데닉스 (케이만) 리미티드플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
US7608600B2 (en)2002-06-282009-10-27Idenix Pharmaceuticals, Inc.Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003269902A1 (en)2002-07-162004-02-02Isis Pharmaceuticals, Inc.Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004009020A2 (en)2002-07-242004-01-29Merck & Co., Inc.Pyrrolopyrimidine thionucleoside analogs as antivirals
US20040067877A1 (en)2002-08-012004-04-08Schinazi Raymond F.2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
US20040229840A1 (en)2002-10-292004-11-18Balkrishen BhatNucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2004046331A2 (en)2002-11-152004-06-03Idenix (Cayman) Limited2’-branched nucleosides and flaviviridae mutation
TWI332507B (en)2002-11-192010-11-01Hoffmann La RocheAntiviral nucleoside derivatives
CA2509687C (en)2002-12-122012-08-14Idenix (Cayman) LimitedProcess for the production of 2'-branched nucleosides
US7601709B2 (en)2003-02-072009-10-13Enanta Pharmaceuticals, Inc.Macrocyclic hepatitis C serine protease inhibitors
AR043006A1 (es)2003-02-122005-07-13Merck & Co IncProceso para preparar ribonucleosidos ramificados
US7452901B2 (en)2003-04-252008-11-18Gilead Sciences, Inc.Anti-cancer phosphonate analogs
WO2004096285A2 (en)2003-04-252004-11-11Gilead Sciences, Inc.Anti-infective phosphonate conjugates
WO2005002626A2 (en)2003-04-252005-01-13Gilead Sciences, Inc.Therapeutic phosphonate compounds
SG182849A1 (en)2003-04-252012-08-30Gilead Sciences IncAntiviral phosphonate analogs
EP1656093A2 (en)2003-05-142006-05-17Idenix (Cayman) LimitedNucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2005020885A2 (en)2003-05-212005-03-10Isis Pharmaceuticals, Inc.Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
EP2604620B9 (en)2003-05-302024-10-23Gilead Pharmasset LLCModified fluorinated nucleoside analogues
DE602004003389T2 (de)2003-06-192007-09-13F. Hoffmann-La Roche AgVerfahren zur herstellung von 4'-azidonukleosidderivaten
GB0317009D0 (en)2003-07-212003-08-27Univ CardiffChemical compounds
US20050043266A1 (en)2003-07-252005-02-24Sumedha JayasenaShort interfering RNA as an antiviral agent for hepatitis C
CA2541634A1 (en)2003-10-102005-04-28Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly hcv ns3-ns4a protease
GB0401088D0 (en)2004-01-192004-02-18Univ CardiffPhosphoramidate derivatives
SG136123A1 (en)2004-03-042007-10-29Leuven K U Res & DevPhosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2005123087A2 (en)2004-06-152005-12-29Merck & Co., Inc.C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
RU2007102281A (ru)2004-06-232008-07-27Айденикс (Кайман) Лимитед (Ky)5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae
CN1972696B (zh)2004-06-242010-08-11默沙东公司用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯
WO2006000085A1 (en)2004-06-282006-01-05Boehringer Ingelheim International GmbhHepatitis c inhibitor peptide analogs
CN101023094B (zh)2004-07-212011-05-18法莫赛特股份有限公司烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PL216369B1 (pl)2004-07-272014-03-31Gilead SciencesPochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
CA2577526A1 (en)2004-08-232006-03-02Joseph Armstrong MartinAntiviral 4'-azido-nucleosides
JP2008511633A (ja)2004-08-272008-04-17シェーリング コーポレイションC型肝炎ウィルスns3セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
WO2007001406A2 (en)2004-10-052007-01-04Chiron CorporationAryl-containing macrocyclic compounds
US20080280842A1 (en)2004-10-212008-11-13Merck & Co., Inc.Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
US8399428B2 (en)2004-12-092013-03-19Regents Of The University Of MinnesotaNucleosides with antiviral and anticancer activity
MX2007010460A (es)2005-02-282007-11-08Genelabs Tech IncCompuestos de nucleosido triciclico para tratar infecciones virales.
US8802840B2 (en)2005-03-082014-08-12Biota Scientific Management Pty Ltd.Bicyclic nucleosides and nucleotides as therapeutic agents
EP1898934A1 (en)2005-03-092008-03-19Idenix (Cayman) LimitedNucleosides with non-natural bases as anti-viral agents
AR056327A1 (es)*2005-04-252007-10-03Genelabs Tech IncCompuestos de nucleosidos para el tratamiento de infecciones virales
JP4705164B2 (ja)2005-05-022011-06-22メルク・シャープ・エンド・ドーム・コーポレイションHcvns3プロテアーゼ阻害剤
WO2007027248A2 (en)2005-05-162007-03-08Valeant Research & Development3', 5' - cyclic nucleoside analogues for treatment of hcv
JP2009513564A (ja)2005-08-092009-04-02メルク エンド カムパニー インコーポレーテッドRna依存性rnaウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体
CA2618713A1 (en)2005-08-122007-02-22Merck & Co., Inc.Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
JP2009504704A (ja)2005-08-152009-02-05エフ.ホフマン−ラ ロシュ アーゲー抗ウイルス4′−置換プロヌクレオチドホスホルアミダート
EA200800932A1 (ru)2005-09-262008-10-30Фармассет, Инк.Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
CN101511375B (zh)2005-12-022012-09-05耶鲁大学L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
BRPI0619563A2 (pt)2005-12-092011-10-04Pharmasset Incnucleosìdeos antivirais
ES2422290T3 (es)2005-12-232013-09-10Idenix Pharmaceuticals IncProcedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
AU2007215114A1 (en)2006-02-142007-08-23Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
CN101460488A (zh)2006-04-042009-06-17弗·哈夫曼-拉罗切有限公司用于hcv治疗的3’,5’-二-o-酰化核苷
US7842672B2 (en)2006-07-072010-11-30Gilead Sciences, Inc.Phosphonate inhibitors of HCV
MX2009003398A (es)2006-09-272009-08-12Coley Pharm GmbhAnalogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
MY145314A (en)2006-10-102012-01-13Medivir AbHcv nucleoside inhibtor
KR101057239B1 (ko)2006-10-102011-08-16에프. 호프만-라 로슈 아게뉴클레오사이드 리보푸라노실 피리미딘의 제조
GB0623493D0 (en)2006-11-242007-01-03Univ CardiffChemical compounds
JP2010512365A (ja)2006-12-112010-04-22エフ.ホフマン−ラ ロシュ アーゲー4’−アジドシチジン誘導体の製造方法
US8148349B2 (en)2006-12-202012-04-03Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7951789B2 (en)2006-12-282011-05-31Idenix Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
US20100056468A1 (en)2007-01-082010-03-04University Health NetworkPyrimidine Derivatives As Anticancer Agents
WO2008100447A2 (en)2007-02-092008-08-21Gilead Sciences, Inc.Nucleoside analogs for antiviral treatment
US7964580B2 (en)2007-03-302011-06-21Pharmasset, Inc.Nucleoside phosphoramidate prodrugs
CN101784557A (zh)2007-05-142010-07-21Rfs制药公司用于治疗病毒感染的叠氮基嘌呤核苷
US20090048189A1 (en)2007-08-152009-02-19Genelabs Technologies, Inc.Tricyclic-nucleoside compounds for treating viral infections
GB0718575D0 (en)2007-09-242007-10-31Angeletti P Ist Richerche BioNucleoside derivatives as inhibitors of viral polymerases
US20090318380A1 (en)2007-11-202009-12-24Pharmasset, Inc.2',4'-substituted nucleosides as antiviral agents
WO2009086192A1 (en)2007-12-212009-07-09Alios Biopharma, Inc.Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
WO2009146123A2 (en)2008-04-032009-12-03Spring BankCompositions and methods for treating viral infections
CN104262345B (zh)2008-04-232017-06-23吉利德科学公司用于抗病毒治疗的1’‑取代的carba‑核苷类似物
US8173621B2 (en)2008-06-112012-05-08Gilead Pharmasset LlcNucleoside cyclicphosphates
CN102177172A (zh)2008-07-022011-09-07埃迪尼克斯医药公司用于治疗病毒感染的化合物和药物组合物
WO2010002877A2 (en)2008-07-032010-01-07Biota Scientific ManagementBycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en)2008-09-032008-10-08Angeletti P Ist Richerche BioAntiviral agents
WO2010039548A2 (en)2008-09-232010-04-08Alnylam Pharmaceuticals, Inc.Chemical modifications of monomers and oligonucleotides with cycloaddition
PT2376088T (pt)2008-12-232017-05-02Gilead Pharmasset LlcFosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
CN102325783A (zh)*2008-12-232012-01-18法莫赛特股份有限公司嘌呤核苷的合成
BRPI0922508A8 (pt)2008-12-232016-01-19Pharmasset IncAnálogos de nucleosídeo
JP2012514657A (ja)2009-01-092012-06-28ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツドウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
GB0900914D0 (en)2009-01-202009-03-04Angeletti P Ist Richerche BioAntiviral agents
BRPI1005401A2 (pt)2009-02-062019-04-02Rfs Pharma, Llcpro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais
UA112140C2 (uk)2009-02-102016-07-25Гіліад Сайєнсіз, Інк.Нуклеозидні похідіні (варіанти), фармацевтична композиція на їх основі, спосіб лікування вірусної інфекції та застосування сполуки для виробництва лікарського засобу
EP2408306A4 (en)2009-03-202012-11-07Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
WO2010108135A1 (en)2009-03-202010-09-23Alios Biopharma, Inc.Protected nucleotide analogs
US8618076B2 (en)2009-05-202013-12-31Gilead Pharmasset LlcNucleoside phosphoramidates
TWI583692B (zh)2009-05-202017-05-21基利法瑪席特有限責任公司核苷磷醯胺
WO2010135520A1 (en)2009-05-202010-11-25Chimerix, Inc.Compounds, compositions and methods for treating viral infection
NZ597535A (en)2009-07-062013-12-20Trilink BiotechnologiesChemically modified ligase cofactors, donors and acceptors
US8455451B2 (en)2009-09-212013-06-04Gilead Sciences, Inc.2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en)2009-09-212011-07-05Gilead Sciences, Inc.2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US20100077085A1 (en)2009-09-232010-03-25Joseph Chyam CohenSystems and method for configuring display resolution in a terminal server environment
US8552021B2 (en)2009-09-292013-10-08Janssen Products, L.P.Phosphoramidate derivatives of nucleosides
AP2012006310A0 (en)2009-11-162012-06-30Univ Georgia2'fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections.
US8816074B2 (en)2009-11-162014-08-26University of Georgia Foundation, Inc.2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
BR112012015951A2 (pt)2010-01-282018-10-16Hoffmann La Roche4 azido-nucleosídeos como compostos anti-hcv
CA2791630A1 (en)2010-03-042011-09-09Enanta Pharmaceuticals, Inc.Combination pharmaceutical agents as inhibitors of hcv replication
ES2900773T3 (es)2010-03-312022-03-18Gilead Pharmasset LlcComprimido que comprende (S)-isopropilo 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato cristalino
US8563530B2 (en)2010-03-312013-10-22Gilead Pharmassel LLCPurine nucleoside phosphoramidate
CA2795054A1 (en)*2010-04-012011-10-06Idenix Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
TW201201815A (en)2010-05-282012-01-16Gilead Sciences Inc1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US20110306541A1 (en)2010-06-102011-12-15Gilead Sciences, Inc.Methods for treating hcv
JP5937073B2 (ja)2010-07-192016-06-22ギリード・サイエンシズ・インコーポレーテッドジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
TW201305185A (zh)2010-09-132013-02-01Gilead Sciences Inc用於抗病毒治療之2’-氟取代之碳-核苷類似物
EA025341B1 (ru)2010-09-222016-12-30Алиос Биофарма, Инк.Замещенные аналоги нуклеотидов
WO2012040124A1 (en)2010-09-222012-03-29Alios Biopharma, Inc.Azido nucleosides and nucleotide analogs
WO2012040126A1 (en)*2010-09-222012-03-29Alios Biopharma, Inc.Substituted nucleotide analogs
WO2012048013A2 (en)2010-10-062012-04-12Inhibitex, Inc.Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
ES2605433T3 (es)2010-11-102017-03-14Janssen Products, L.P.Fosforamidatos de espironucleósido oxetánico uracílico
US9012428B2 (en)2010-11-102015-04-21Janssen Products, LpUracyl spirooxetane nucleoside phosphoramidates
TW201242974A (en)2010-11-302012-11-01Gilead Pharmasset LlcCompounds
US20130273005A1 (en)2010-12-202013-10-17Gilead Sciences, Inc.Methods for treating hcv
EP2655392B1 (en)2010-12-222018-04-18Alios Biopharma, Inc.Cyclic nucleotide analogs
EP2658857B1 (en)2010-12-292016-11-02Inhibitex, Inc.Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2012094248A1 (en)2011-01-032012-07-12Nanjing Molecular Research, Inc.O-(substituted benzyl) phosphoramidate compounds and therapeutic use
US9156874B2 (en)2011-01-032015-10-13Nanjing Molecular Research, Inc.Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
US9085599B2 (en)2011-03-162015-07-21Enanta Pharmaceuticals, Inc.2′allene-substituted nucleoside derivatives
WO2012154321A1 (en)2011-03-312012-11-15Idenix Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
KR20140019832A (ko)2011-04-132014-02-17길리애드 사이언시즈, 인코포레이티드항바이러스 치료를 위한 1''-치환 피리미딘 ν-뉴클레오사이드 유사체
EP2697242B1 (en)2011-04-132018-10-03Merck Sharp & Dohme Corp.2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN103582420B (zh)*2011-04-132016-10-19默沙东公司2’-取代的核苷衍生物和使用其治疗病毒病的方法
CA2832449A1 (en)2011-04-132012-10-18Vinay GIRIJAVALLABHAN2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012158811A2 (en)2011-05-192012-11-22Rfs Pharma, LlcPurine monophosphate prodrugs for treatment of viral infections
WO2013009737A1 (en)2011-07-132013-01-17Merck Sharp & Dohme Corp.5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
WO2013009735A1 (en)2011-07-132013-01-17Merck Sharp & Dohme Corp.5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CN103987712B (zh)2011-07-192016-05-04河南美泰宝生物制药有限公司2’,3’-二脱氧-2’-α-氟-2’-β-C-甲基核苷和其前药
AR088441A1 (es)2011-09-122014-06-11Idenix Pharmaceuticals IncCompuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
CA2847892A1 (en)2011-09-122013-03-21Idenix Pharmaceuticals, Inc.Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013044030A1 (en)2011-09-232013-03-28Enanta Pharmaceuticals, Inc.2'-chloroacetylenyl substituted nucleoside derivatives
EP2768838A1 (en)2011-10-142014-08-27IDENIX Pharmaceuticals, Inc.Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en)2011-11-292014-11-18Gilead Pharmasset LlcCompositions and methods for treating hepatitis C virus
WO2013084165A1 (en)2011-12-052013-06-13Medivir AbHcv polymerase inhibitors
UA111761C2 (uk)2011-12-202016-06-10Рібосаєнс Ллс2',4'-дифтор-2'-метилзаміщені нуклеозидні похідні як інгібітори реплікації phk вірусу гепатиту c
CN104011060A (zh)2011-12-202014-08-27弗·哈夫曼-拉罗切有限公司作为hcv rna复制抑制剂的4‘-叠氮基,3’-氟取代的核苷衍生物
US20140356325A1 (en)2012-01-122014-12-04Ligand Pharmaceuticals IncorporatedNovel 2'-c-methyl nucleoside derivative compounds
CA2873315A1 (en)2012-05-222013-11-28Idenix Pharamaceuticals, Inc.D-amino acid compounds for liver disease
US9109001B2 (en)2012-05-222015-08-18Idenix Pharmaceuticals, Inc.3′,5′-cyclic phosphoramidate prodrugs for HCV infection
US9296778B2 (en)2012-05-222016-03-29Idenix Pharmaceuticals, Inc.3′,5′-cyclic phosphate prodrugs for HCV infection
EP2900682A1 (en)2012-09-272015-08-05IDENIX Pharmaceuticals, Inc.Esters and malonates of sate prodrugs
TR201809048T4 (tr)2012-10-082018-07-23Centre Nat Rech ScientHcv enfeksiyonu için 2'-kloro nükleosit analogları.
AR092959A1 (es)2012-10-172015-05-06Merck Sharp & DohmeDerivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US9457039B2 (en)2012-10-172016-10-04Merck Sharp & Dohme Corp.2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9242988B2 (en)2012-10-172016-01-26Merck Sharp & Dohme Corp.2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2909223B1 (en)2012-10-192017-03-22Idenix Pharmaceuticals LLCDinucleotide compounds for hcv infection
WO2014066239A1 (en)2012-10-222014-05-01Idenix Pharmaceuticals, Inc.2',4'-bridged nucleosides for hcv infection
WO2014078427A1 (en)2012-11-142014-05-22Idenix Pharmaceuticals, Inc.D-alanine ester of rp-nucleoside analog
US20140140952A1 (en)2012-11-142014-05-22Idenix Pharmaceuticals, Inc.D-Alanine Ester of Sp-Nucleoside Analog
US20140205566A1 (en)2012-11-302014-07-24Novartis AgCyclic nucleuoside derivatives and uses thereof
US9211300B2 (en)2012-12-192015-12-15Idenix Pharmaceuticals Llc4′-fluoro nucleosides for the treatment of HCV
WO2014124430A1 (en)2013-02-112014-08-14Emory UniversityNucleotide and nucleoside therapeutic compositions and uses related thereto
US9309275B2 (en)2013-03-042016-04-12Idenix Pharmaceuticals Llc3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en)2013-03-042014-09-12Idenix Pharmaceuticals, Inc.Thiophosphate nucleosides for the treatment of hcv
EP2970357B1 (en)2013-03-132025-01-01Idenix Pharmaceuticals LLCAmino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
RU2534613C2 (ru)2013-03-222014-11-27Александр Васильевич ИващенкоАлкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
CN103848876B (zh)2013-03-252016-05-11安徽贝克联合制药有限公司一种核苷磷酰胺前药及其制备方法和其应用
EP2981542B1 (en)2013-04-012021-09-15Idenix Pharmaceuticals LLC2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en)2013-06-052019-08-07Idenix Pharmaceuticals LLC.1',4'-thio nucleosides for the treatment of hcv
EP3010512B1 (en)2013-06-182017-12-27Merck Sharp & Dohme Corp.Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3027636B1 (en)2013-08-012022-01-05Idenix Pharmaceuticals LLCD-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015061683A1 (en)2013-10-252015-04-30Idenix Pharmaceuticals, Inc.D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
US20160271162A1 (en)2013-11-012016-09-22Idenix Pharmacueticals, LlcD-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
US20160280729A1 (en)2013-11-202016-09-29Idenix Pharmaceuticals LlcCyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
EP3074411A2 (en)2013-11-272016-10-05Idenix Pharmaceuticals LLCNucleotides for the treatment of liver cancer
WO2015081297A1 (en)2013-11-272015-06-04Idenix Pharmaceuticals, Inc.2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
CN103848877B (zh)2013-12-162016-08-24安徽贝克联合制药有限公司核苷环磷酸酯化合物及其制备方法和其应用
WO2015095305A1 (en)2013-12-172015-06-25Idenix Pharmaceuticals, Inc.Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
WO2015095419A1 (en)2013-12-182015-06-25Idenix Pharmaceuticals, Inc.4'-or nucleosides for the treatment of hcv
US20170066795A1 (en)2014-03-052017-03-09Idenix Pharmaceuticals LlcSolid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
US10202411B2 (en)2014-04-162019-02-12Idenix Pharmaceuticals Llc3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV

Also Published As

Publication numberPublication date
MD20150036A2 (ro)2015-08-31
ZA201502545B (en)2017-08-30
ECSP15015737A (es)2015-12-31
MX2015004348A (es)2015-10-29
WO2014058801A1 (en)2014-04-17
NI201500049A (es)2016-02-16
MX353422B (es)2018-01-12
JP2015535853A (ja)2015-12-17
CL2015000870A1 (es)2015-11-13
CN104936970A (zh)2015-09-23
ES2674980T3 (es)2018-07-05
IL238088A0 (en)2015-05-31
KR20150084830A (ko)2015-07-22
EP2906579A1 (en)2015-08-19
AU2013329521A1 (en)2015-05-28
EA030189B1 (ru)2018-07-31
US10513534B2 (en)2019-12-24
NZ706985A (en)2018-08-31
PE20151318A1 (es)2015-10-03
US20140099283A1 (en)2014-04-10
DOP2015000079A (es)2015-11-30
EA201500304A1 (ru)2016-01-29
AP2015008384A0 (en)2015-04-30
CN111848711A (zh)2020-10-30
JP6495822B2 (ja)2019-04-03
BR112015007698A2 (pt)2017-08-22
CA2887578A1 (en)2014-04-17
EA030189B8 (ru)2018-10-31
HK1207647A1 (en)2016-02-05
AU2013329521B2 (en)2018-04-19
US20160083413A1 (en)2016-03-24
CR20150199A (es)2015-09-01
GEP201706723B (en)2017-08-25
KR102001280B1 (ko)2019-07-17
TN2015000117A1 (en)2016-06-29
SG11201502750UA (en)2015-06-29
EP2906579B1 (en)2018-04-18
PH12015500749A1 (en)2015-05-25
TR201809048T4 (tr)2018-07-23

Similar Documents

PublicationPublication DateTitle
GT201500086A (es)Análogos de 2'-cloro nucleósido para infección por vhc
DOP2014000260A (es)Compuestos d-aminoácidos para enfermedad hepática
ECSP18069924A (es)Compuestos tetracíclicos de piridona como antivirales
CL2017001426A1 (es)Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
MX2012011222A (es)Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
UY32793A (es)Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
MX2015011473A (es)Compuesto de fosforamidato de nucleosido novedoso y su uso.
UY33775A (es)Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
NI201300107A (es)Derivados de nucleósidos 2' - sustituidos y métodos de uso de los mismos para el tratamiento de enfermedades virales.
BR112015023017A2 (pt)combinação de dois antivirais para o tratamento de hepatite c
CL2013000727A1 (es)Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c.
ECSP12012104A (es)Inhibidores de virus flaviviridae
CO7240410A2 (es)Inhibidores macrocíclicos de virus flaviviridae
GEP20247600B (en)B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
ECSP15035530A (es)Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
EA021554B9 (ru)Органические соединения и их применение для лечения hcv инфекции
WO2015077360A3 (en)Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
IN2014CN00572A (es)
ECSP11011101A (es)Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
CL2012003341A1 (es)Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
NI201100180A (es)Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona
CO7200247A2 (es)Compuestos d-aminoácidos para enfermedad hepática
CR20140533A (es)Compuestos d-aminoácidos para enfermedad hepática
CL2013000210A1 (es)Compuestos derivados de tiofeno 2,3,5 trisustituidos; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento de un trastorno o enfermedad en un sujeto causado o asociado con una infeccion por vhc, tales como cirrosis hepatica, carcinoma hepatocelular, entre otras.
NI201400136A (es)Compuestos d - aminoácidos para enfermedad hepática

[8]ページ先頭

©2009-2025 Movatter.jp